Industry Focus

Pot stock HEXO is under fire over its use of social media advertising and if that isn't bad enough, its home province, Quebec, has proposed restrictions on marijuana edibles that could disrupt its growth plans. Is it game over for HEXO? Also, here's why  biopharma giant Pfizer is merging its off-patent drug portfolio with generic drug heavy weight Mylan. 

Check out more of our content here:

Direct download: 20190731_IF_Healthcare.mp3
Category:Podcast -- posted at: 3:30pm EDT